Pharmaceuticals

AtaiBeckley

AtaiBeckley Reports Q1 Net Loss of $29.78M, Stock Rises Amid Valuation Debate

AtaiBeckley released FY2026 Q1 earnings on May 12 (EST), actual revenue USD 954 K (forecast USD 90.91 K), actual EPS USD -0.0833 (forecast USD -0.1087)

Atai Beckley Submits Annual Report, BPL-003 Enters Phase III Clinical Trials

Atai Beckley's Chief Marketing Officer Sold Company Stocks

AtaiBeckley Announces Positive Phase 2 Trial Results for EMP-01, Stock Rises

AtaiBeckley Announces Positive Phase 2a Clinical Trial Results for BPL-003

Atai Beckley announces positive results for BPL-003 in treatment-resistant depression clinical trial

AtaiBeckley released FY2025 Q4 earnings on March 6 (EST), actual revenue USD 1.066 M (forecast USD 229.17 K), actual EPS USD -1.7335 (forecast USD -0.1058)

AtaiBeckley released FY2025 earnings on March 6 (EST), actual revenue USD 4.089 M (forecast USD 3.009 M), actual EPS USD -2.9136 (forecast USD -0.6269)

AtaiBeckley Inc. Reports Significant Increase in FY25 Net Loss

AtaiBeckley Announces Successful Completion of BPL-003 Phase 2 Meeting

AtaiBeckley Inc. to Host Virtual Investor Day to Discuss BPL-003 Phase 3 Clinical Strategy

Atai Beckley Reports Positive Results for BPL-003 in Treating Treatment-Resistant Depression

Atai Beckley NV Obtains New US Patent for Oral R-MDMA Until 2043

Atai Beckley NV released FY2025 Q3 earnings on November 12 (EST), actual revenue USD 749K (forecast USD 55.56K), actual EPS USD -0.2806 (forecast USD -0.1144)

Atai Beckley NV released FY2025 9 Months Earnings on November 12, 2025 (EST) with actual revenue of USD 2.274 M and EPS of USD -0.291

Atai Beckley NV Reports Increased Cash Holdings and Plans to Relocate Corporate Registration

Atai Beckley Announced Third Quarter EPS Loss of $0.28

Atai Beckley N.V. reports Q3 revenue of $749,000

Atai Beckley NV Secures NIDA Funding and Receives FDA Breakthrough Therapy Designation

OPTIMI HEALTH CORP

HCW Biologics

Silexion Therapeutics

Vida Global

GCL Global

BiomX

MetaVia

Micware

MicroAlgo

ATAI

AtaiBeckley (ATAI) reported a Q1 net loss of $29.78 million, but improved its loss per share to $0.08 from $0.15. Despite ongoing losses, the stock has seen a 3.36% one-day increase and a 9.21% gain over 90 days. The company's price-to-book ratio stands at 7.7x, indicating it may be overvalued compared to industry averages. However, a discounted cash flow analysis suggests it could be undervalued by 30.9%. Investors are advised to weigh risks and rewards carefully.

Simplywall

Assessing AtaiBeckley (ATAI) Valuation After First Quarter Loss And Improved Per Share Results

PHAR

LABU

Analysts highlight three high-risk, high-reward stocks for potential explosive gains: Inventiva (IVA), Pharming Group (PHAR), and Atai Life Sciences (ATAI). Inventiva is focused on lanifibranor, a promising drug for treating nonalcoholic steatohepatitis (NASH), with early Phase III trial data showing positive results. The stock has a Strong Buy consensus rating, and the average price target suggests a 193.3% upside from its current price of $15.75. Investors are encouraged to consider these stocks for significant market opportunities.

Tip Ranks

Inventiva SA

Pharming Group NV

iShares Global Healthcare

Direxion S&P Biotech Bull 3X

SPDR S&P Biotech

VG Health

3 High-Risk, High-Reward Stocks to Buy Now for Explosive Upside, According to Analysts – 5/8/2026

TEVA

IBBQ

ARKG

This report highlights whale alerts in health care stocks, indicating significant trading activity that may present trading opportunities. The analysis includes various options trades with bullish, bearish, and neutral sentiments across multiple companies, detailing strike prices, expiration dates, total trade prices, and volumes. Notable trades include ATAI's bullish call option and TEVA's bearish call option, among others, providing insights into market movements and potential investment strategies.

benzinga_article

Teva Pharmaceutical Industries

iShares Biotechnology ETF

iShares US Pharma

Invesco Nasdaq Biotechnology ETF

Ark Genomic Revolution ETF

Health Care Select Sector SPDR

Novo Nordisk AS

Intuitive Surgical

Cytokinetics

Guardant Health

Unitedhealth

Abbvie

Eli Lilly

Molina Healthcare

10 Health Care Stocks With Whale Alerts In Today's Session

CMPS

CYBN

PSIL

Trump Wants to Give Psychedelics Stocks a Boost. Can This Leading Company Deliver?

Barchart Option

Compass Pathways

Cybin

AdvisorShares Psychedelics ETF

Trump Wants to Give Psychedelics Stocks a Boost. Can This Leading Company Deliver?

H.C. Wainwright's Patrick Trucchio has reiterated a Buy rating on Atai Beckley N.V. (ATAI) with a price target of $25.00. The analyst has an average return of 27.2% and a success rate of 52.24% on his stock recommendations. The overall analyst consensus for Atai Beckley N.V. is a Strong Buy, with an average price target of $14.80.

Definium Therapeutics

Immunocore

Atai Beckley N.V. (ATAI) Receives a Buy from H.C. Wainwright

DFTX

Executives from psychedelic drug developers discussed advancing large-scale clinical programs and adapting to potential U.S. regulatory changes at the Psychedelics Forum. Following President Trump's executive order to expedite FDA approvals for psychedelic drugs, companies like Compass Pathways highlighted significant progress in their trials for treatment-resistant depression. Other firms, including Definium and AtaiBeckley, outlined their development timelines and strategies. Panelists praised FDA engagement but noted challenges with DEA coordination, emphasizing the need for clearer regulations. Overall, the industry is optimistic about upcoming developments and potential rescheduling of psychedelic substances.

Market Beat

Error: Response status code does not indicate success: 503 (Service Unavailable).

AtaiBeckley and PsyPAN Receive a Silver Award in 2026 Patient Participant Index, Reflecting Ongoing Commitment to Participant-Informed Research | ATAI Stock News

StockTitan

AtaiBeckley and PsyPAN Receive a Silver Award in 2026 Patient Participant Index, Reflecting Ongoing Commitment to Participant-Informed Research | ATAI Stock News

AtaiBeckley(ATAI.US)

Assessing AtaiBeckley (ATAI) Valuation After First Quarter Loss And Improved Per Share Results

3 High-Risk, High-Reward Stocks to Buy Now for Explosive Upside, According to Analysts – 5/8/2026

10 Health Care Stocks With Whale Alerts In Today's Session

Trump Wants to Give Psychedelics Stocks a Boost. Can This Leading Company Deliver?

Atai Beckley N.V. (ATAI) Receives a Buy from H.C. Wainwright

Error: Response status code does not indicate success: 503 (Service Unavailable).

AtaiBeckley and PsyPAN Receive a Silver Award in 2026 Patient Participant Index, Reflecting Ongoing Commitment to Participant-Informed Research | ATAI Stock News